Treatment of symptomatic, chronic heart failure (HF) with reduced (HFrEF, EF≤40%), mildly-reduced (HFmrEF, EF 41-49%) and preserved (HFpEF, EF>50%) ejection fraction. In Spain, it is funded for HFrEF patients with increased NT-proBNP levels and not controlled with recommended first-line therapies (ACE inhibitors or ARBs or sacubitril/valsartan with beta-blocker and mineralocorticoid receptor antagonist; unless intolerance or contraindication), as well as in symptomatic HFpEF with increased NT-proBNP levels. It is also labeled for the treatment of type 2 diabetes mellitus.